Metabolome

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

Retrieved on: 
Tuesday, April 9, 2024
Shenzhen University, Molecular biology, Immunology, Nature Methods, Advanced technology, Proteome, Ageing, Speech, Genesis (journal), Data analysis, Southern Medical University, Neuroscience, Translation, Human Cell Atlas, Nature Communications, Biochemistry, Neurology, Communication, Transcriptome, Genetics, Research, Genome, Epigenome, Immunity, Microbiology, Metabolome, Diagnosis, Peking University, Health, Conference, GSA, Executive, Cancer, Fudan University, Reproduction, Biology, National academy, Zhejiang University, Medicine

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.

Key Points: 
  • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.
  • With the theme "Technologic Innovation, Scientific Discovery, Translational Application", TICSSO-2 focused on the latest advances in single-cell and spatial omics.
  • On March 31st and April 1st were four online international forums, with one specifically for young researchers.
  • TICSSO-2 is hailed as the largest, most influential, and highest academic conference in the field of single-cell and spatial omics in the world.

Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform

Retrieved on: 
Sunday, January 7, 2024
Cloud, Epigenome, Partnership, Transcriptome, Akoya, Mary Ann Liebert, Laboratory, Genomics, AI, University, Proteomics, Proteome, Metabolome, Nature, Genetic, GEN, Acceleration, Medical imaging

MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, in collaboration with Enable Medicine, a leading provider of AI-powered biological insights, announces the availability of MaxFuse, an advanced algorithm co-developed in the laboratory of Dr. Garry Nolan for integrating multiomic single-cell and spatial datasets*. Dr. Nolan is a co-founder and member of the Board of Directors of Akoya Biosciences.

Key Points: 
  • Dr. Nolan is a co-founder and member of the Board of Directors of Akoya Biosciences.
  • Recent technology advancements have enabled analyses of the proteome, metabolome, transcriptome, and epigenome both spatially and at the single-cell level.
  • “MaxFuse represents a significant advancement in the analytics capabilities needed to maximize the value of data derived from spatial and single-cell technologies.
  • * MaxFuse was developed in collaboration with the laboratories of Nancy Zhang and Zongming Ma at the University of Pennsylvania.

Olaris, Inc. debuts novel global QqQ LC mass spectrometry panel for clinical metabolomics applications at the American Society for Mass Spectrometry 2023 Meeting

Retrieved on: 
Monday, June 5, 2023
Pharmacy, American Society for Mass Spectrometry, Drug development, ASMS, QQQ, NMR, Mass spectrometry, Research, Biomarker, Metabolome, MS, Machine learning, Metabolomics, Medicine, Annual general meeting, Society, Medical imaging

FRAMINGHAM, Mass., June 5, 2023 /PRNewswire-PRWeb/ -- Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning to discover and develop its myOLARIS™ diagnostics products, is pleased to announce that the company's research on developing a triple-quadrupole (QqQ) mass spectrometry (MS) platform for clinical metabolomics applications has been selected for a poster presentation on June 5th at the upcoming American Society for Mass Spectrometry (ASMS) 2023 Annual Meeting, to be held June 4th-8th in Houston, TX.

Key Points: 
  • Combined with their existing high-field multidimensional NMR technology, the new Olaris QqQ panel enables global, quantitative reproducible measurements of hundreds of metabolites for clinical and biopharmaceutical research.
  • "The new QqQ technology will expand our ability to detect clinically impactful changes in metabolites.
  • Yet due to challenges with analytical measurements and reproducibility concerns, metabolomics has yet to reach its full potential in diagnostic and drug development.
  • For more information on the ASMS meeting or to view the Olaris presentation during the conference, visit http://www.asms.org .

Data Published in Nature Metabolism Show Envivo Bio’s Ingestible Device Uniquely Profiles Dietary and Lipid Compounds in the Human Metabolome

Retrieved on: 
Wednesday, May 10, 2023
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, Extrapyramidal system, University, Molecular and Cellular Biology, Bio, Digestion, University of California, Davis, Lipid, Research, Biomarker, Metabolome, Nature Metabolism, Medical imaging, Nature

CapScan is a non-invasive, ingestible collection device that is the size of a standard vitamin pill.

Key Points: 
  • CapScan is a non-invasive, ingestible collection device that is the size of a standard vitamin pill.
  • Each device has a pH-targeted enteric coating, designed to dissolve at a pre-set rate based on the distinct pH levels of the various regions of the human intestines.
  • In addition, researchers found significant variability of the metabolome along the intestinal tract itself, highlighting the regional and dynamic nature of the gut.
  • “Routine access to intestinal samples will advance research into human nutrition, and could potentially lead to new therapies to human disease.”

New Data Published in Nature Show Envivo Bio’s Ingestible Device Provides Novel Insights Into the Human Microbiome and Metabolome

Retrieved on: 
Wednesday, May 10, 2023
Medical Devices, Health, Research, Pharmaceutical, Science, Biotechnology, Extrapyramidal system, University, Gastrointestinal tract, Stanford University, Bio, Pennsylvania State University, Physiology, Proteome, Multimedia, Endoscopy, Metabolome, Nature Metabolism, Trial of the century, Mother, Stanford University School of Medicine, Chan Zuckerberg Biohub, Bill, Biological engineering, Immunology, Ecosystem, Bill & Melinda Gates Foundation, Rachel Shalon, Max Planck Society, University of California, Davis, Disease, Antibiotics, Pharmaceutical industry, Gum arabic, Nature, Microbiology, Medicine

Envivo Bio, a biotech company advancing the gut microbiome and metabolome field, announced that new data published in Nature show the company’s proprietary CapScan® intestinal sampling device can non-invasively and accurately profile the human gut microbiome and metabolome under physiological conditions for the first time.

Key Points: 
  • Envivo Bio, a biotech company advancing the gut microbiome and metabolome field, announced that new data published in Nature show the company’s proprietary CapScan® intestinal sampling device can non-invasively and accurately profile the human gut microbiome and metabolome under physiological conditions for the first time.
  • View the full release here: https://www.businesswire.com/news/home/20230510005094/en/
    Envivo Bio's CapScan is a non-invasive, ingestible intestinal sampling device that sheds light on human gut activities that were previously unmeasurable via endoscopy and stool samples.
  • Findings from a landmark study published in Nature suggest that CapScan, the first and only device of its kind, has the potential to accelerate microbiome-related research and biopharmaceutical drug-discovery and development programs.
  • The researchers report significant differences in microbiome composition, gene-class abundance, prophage induction, and the host proteome along various regions of the human intestine.

Lifespin Announces Inaugural Membership in the Industrial Participant Program of the Wyss Diagnostics Accelerator at Harvard University

Retrieved on: 
Thursday, April 20, 2023
Software, Research, General Health, Mobile, Wireless, Data Management, Apps, Applications, Technology, Medical Devices, Artificial Intelligence, Health Technology, Science, Health, Other Science, Yale University, Software as a service, CT, Obesity, Therapeutic drug monitoring, Diabetes, Engineering, NMR, Cone Health Women's Hospital, Inflammation, Metabolomics, DSM-IV codes, A.I, Risk, Biomarker, Harvard University, Metabolome, Wyss Institute for Biologically Inspired Engineering, IPP, RUO, Cell biology, Metabolism, Pathology, Patient, Wyss Institute, Cancer, Artificial intelligence, Hospital, Wyss, Neurology, Disease, Medical device, Medical imaging

Lifespin GmbH, based in Regensburg with offices in Boston, Massachusetts, announced today that it is one of 24 inaugural members of the Wyss Institute for Biologically Inspired Engineering at Harvard University’s Diagnostics Accelerator ( Wyss DxA ) Industrial Participant Program (IPP).

Key Points: 
  • Lifespin GmbH, based in Regensburg with offices in Boston, Massachusetts, announced today that it is one of 24 inaugural members of the Wyss Institute for Biologically Inspired Engineering at Harvard University’s Diagnostics Accelerator ( Wyss DxA ) Industrial Participant Program (IPP).
  • Originally formed in 2021 as a pilot program, the IPP recently has transitioned from its pilot phase into an official program within the Harvard system, and consolidated its base of initial industrial partners, including Lifespin.
  • “The mission of the Wyss DxA is to get transformative diagnostic tests to market and reduce disease burden for patients with major unmet needs.
  • Lifespin ( www.lifespin.health ) is a deep data company that seeks to detect distinct deviations in the human metabolism caused by diseases.

PrognomiQ Strengthens its Scientific and Clinical Leadership with the Appointment of Brian Koh, M.D. as Chief Medical Officer

Retrieved on: 
Tuesday, November 29, 2022
Gilead Sciences, Proteomics, SAN, Transcriptome, Pharmacology, Genomics, Cancer, Yale University, Therapy, Epigenome, Oncology, Hotel manager, Biomarker, Internal medicine, Genome, Metabolomics, Medicine, Kite Pharma, Hematology, Health, Harvard College, Mayo, Metabolome, Pharmaceutical industry, Medical imaging

SAN MATEO, Calif., Nov. 29, 2022 /PRNewswire/ -- PrognomiQ – a healthcare company focused on harnessing the power of multi-omics data to transform the detection and early treatment selection and monitoring of cancer and other complex diseases – today announced that it has appointed Brian Koh, M.D., as its Chief Medical Officer. In this new role, Dr. Koh will be responsible for developing and executing the company's clinical development and medical strategy, serving on PrognomiQ's Executive Team.

Key Points: 
  • In this new role, Dr. Koh will be responsible for developing and executing the company's clinical development and medical strategy, serving on PrognomiQ's Executive Team.
  • Furthermore, Dr. Koh's addition to PrognomiQ's leadership team broadens the deep technical expertise of the company in proteomics, multi-omics and data sciences."
  • In furthering the company's commitment and leadership position in multi-omics, PrognomiQ also promoted Bruce Wilcox, Ph.D. to the position of Chief Technology Officer.
  • PrognomiQ uses leading edge proteomics technologies, in addition to metabolomics and genomics technologies, to develop multi-omics products to improve human health.

FIU wins $19.4M NIH grant to fight health disparities

Retrieved on: 
Tuesday, November 15, 2022
Growth, Florida International University, Social work, Epidemiology, Microbiota, Health, FIU Robert Stempel College of Public Health and Social Work, Dementia, Woman, Pennington Biomedical Research Center, FIU, Risk, Sleep, Research institute, FDA, Metabolome, HIV, Research, Patient, Stempel, COVID-19, Black, NIH, Cognition, Public health, National, Mentorship, Science, Alzheimer's disease, Dietitian, Biomarker, Faculty, Minority, Pharmaceutical industry, Medicine

In 2017, FIU's Community-Based Research Institute won a $13.1 million grant from the National Institutes of Health (NIH) to build the Research Center in a Minority Institution at FIU (FIU-RCMI), which focused on world-class, community-partnered health disparities research and training.

Key Points: 
  • In 2017, FIU's Community-Based Research Institute won a $13.1 million grant from the National Institutes of Health (NIH) to build the Research Center in a Minority Institution at FIU (FIU-RCMI), which focused on world-class, community-partnered health disparities research and training.
  • In recognition of the FIU-RCMI's exceptional performance and its plans for expansion, NIH just renewed the FIU-RCMI with a 5-year, $19.4 million grant, which is the university's largest NIH award to date.
  • "The FIU-RCMI has and will continue to drive FIU's outstanding growth in research capacity in the area of health disparities," said FIU President Kenneth A. Jessell.
  • The new grant will allow the FIU-RCMI to expand its scope to:
    Address HIV and COVID-19 disparities among people with HIV.

NOSTER launches Metabolome Analysis Service of metabolites produced by gut microbiota and announces the recipients of the 2022 NOSTER & Science Microbiome Prize

Retrieved on: 
Monday, July 25, 2022
Metagenomics, Association, National, University, AAAS, Apollo, Human, Biomedical sciences, Kyoto University, Research, Graduate school, Associate, American Association, Metabolism, Data analysis, Fats, Metabolomics, Biotechnology, Technology, American Association for Laboratory Animal Science, Research Institute for Advanced Computer Science, Prize, Microsoft Analysis Services, Metabolome, University of Utah, Oil, Pharmacy, Medicine, Dietary supplement, Science

Noster also announced the recipients of the 2022 'NOSTER & Science Microbiome Prize'established by Noster Inc with the American Association for the Advancement of Science (AAAS) publisher of the journal Science.

Key Points: 
  • Noster also announced the recipients of the 2022 'NOSTER & Science Microbiome Prize'established by Noster Inc with the American Association for the Advancement of Science (AAAS) publisher of the journal Science.
  • Based on these findings Noster has built a comprehensive library of original lipid metabolites produced by gut microbiota.
  • Noster makes full use of this technology to provide state of the art 'Metabolome Analysis Service' for exploring the properties of the still unexplored world of gut microbial metabolites.
  • In addition to 'Metabolome Analysis Service', we also provide an 'Gut Microbiota Analysis Service', which can be used in combination to clarify the correlation between gut microbiota and metabolites.

NOSTER launches Metabolome Analysis Service of metabolites produced by gut microbiota and announces the recipients of the 2022 NOSTER & Science Microbiome Prize

Retrieved on: 
Monday, July 25, 2022
Metagenomics, Association, National, University, AAAS, Apollo, Human, Biomedical sciences, Kyoto University, Research, Graduate school, Associate, American Association, Metabolism, Data analysis, Fats, Metabolomics, Biotechnology, Technology, American Association for Laboratory Animal Science, Research Institute for Advanced Computer Science, Prize, Microsoft Analysis Services, Metabolome, University of Utah, Oil, Pharmacy, Medicine, Dietary supplement, Science

Noster also announced the recipients of the 2022 'NOSTER & Science Microbiome Prize'established by Noster Inc with the American Association for the Advancement of Science (AAAS) publisher of the journal Science.

Key Points: 
  • Noster also announced the recipients of the 2022 'NOSTER & Science Microbiome Prize'established by Noster Inc with the American Association for the Advancement of Science (AAAS) publisher of the journal Science.
  • Based on these findings Noster has built a comprehensive library of original lipid metabolites produced by gut microbiota.
  • Noster makes full use of this technology to provide state of the art 'Metabolome Analysis Service' for exploring the properties of the still unexplored world of gut microbial metabolites.
  • In addition to 'Metabolome Analysis Service', we also provide an 'Gut Microbiota Analysis Service', which can be used in combination to clarify the correlation between gut microbiota and metabolites.